<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02798484</url>
  </required_header>
  <id_info>
    <org_study_id>CHUB-CNA</org_study_id>
    <nct_id>NCT02798484</nct_id>
  </id_info>
  <brief_title>Monitoring of Breast Cancers Treated by Neoadjuvant Therapy Via Diffusion-weighted Magnetic Resonance Imaging</brief_title>
  <official_title>Pilot Study: Monitoring of Breast Cancers Treated by Neoadjuvant Therapy Via Diffusion-weighted Magnetic Resonance Imaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brugmann University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brugmann University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Magnetic resonance imaging (MRI) is the method of choice in breast cancer to perform the
      loco-regional staging and direct the treatment.

      European Guidelines (EUSOMA) currently recommend MRI for initial evaluation and assessement
      of the neoadjuvant chemotherapy (NAC) response, for breast cancer. The standard of care
      consists of realizing a MRI before the start of the NAC and another one after it's ended, six
      months later.

      There is currently no consensus on the realization of an interval MRI for early assessment of
      the chemosensitivity of the tumor. It would allow though alterations in the therapeutic
      regimen in the event of a non response. Similarly, there is no consensus on when this
      interval MRI should be performed.

      Some recent studies suggest that Diffusion-weighted Magnetic Resonance Imaging is interesting
      for the evaluation of the early response. However, these are preliminary studies with
      quantitative measures realized by the region of interest (ROI) method. A response to
      neoadjuvant chemotherapy results in elevated values of apparent diffusion coefficients (ADC).

      The investigator's goal for this study is to evaluate the reliability of diffusion as tumor
      biomarker. Therefore, they will study the quantitative analysis of the diffusion-weighted
      magnetic resonance sequences in the pre-therapeutic assessment and the early and late
      follow-up of breast cancers under neoadjuvant treatment (chemotherapy, hormonotherapy...)
      within the CHU Brugmann hospital. The results of this analysis will be compared with the MRI
      results obtained at the end of the treatment and with the histology of the initial biopsy and
      the surgical specimen.

      The expected benefits are:

        -  to establish correlations between apparent diffusion coefficients (ADC) values and
           histology

        -  to observe changes in the ADC according to the type of response: ADC increase in the
           event of partial response, ADC stability in the event of non response, ADC decrease in
           the event of a progression, absence of restriction in the event of a complete response.

        -  to confirm that diffusion weighted MRI within a short interval (after one cure, at one
           month) has a predictive value for the neoadjuvant chemotherapy (NAC) response.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Apparent diffusion coefficient (ADC) (mm2/sec)</measure>
    <time_frame>Baseline: start of the neo-adjuvant therapy</time_frame>
    <description>Apparent diffusion coefficient (ADC) expressed in mm2/sec. Magnetic resonance images realised with the Ingenia 3 Tesla Engine (Philips) and the Area 1,5 Tesla Engine (Siemens).Post-processing realized with the Syngo Onco Care application of Siemens.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent diffusion coefficient (ADC) (mm2/sec)</measure>
    <time_frame>One month after the start of the neo-adjuvant therapy</time_frame>
    <description>Apparent diffusion coefficient (ADC) expressed in mm2/sec. Magnetic resonance images realised with the Ingenia 3 Tesla Engine (Philips) and the Area 1,5 Tesla Engine (Siemens).Post-processing realized with the Syngo Onco Care application of Siemens.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent diffusion coefficient (ADC) (mm2/sec)</measure>
    <time_frame>At the end of the neo-adjuvant therapy (typical duration: 6 months)</time_frame>
    <description>Apparent diffusion coefficient (ADC) expressed in mm2/sec. Magnetic resonance images realised with the Ingenia 3 Tesla Engine (Philips) and the Area 1,5 Tesla Engine (Siemens).Post-processing realized with the Syngo Onco Care application of Siemens.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anatomo-pathology classification - histological type</measure>
    <time_frame>Baseline: start of the neo-adjuvant therapy</time_frame>
    <description>The histological type of the tumor will be determined by the Anatomo-Pathology Department of the CHU Brugmann hospital, according to standard of care. The determination will be performed on the initial biopsy samples used for diagnosis and/or on the surgical specimen.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Breast cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients diagnosed with breast cancer and placed under neo-adjuvant treatment (hormonotherapy, chemotherapy) within the CHU Brugmann hospital.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Diffusion-weighted Nuclear Magnetic Resonance Imaging (MRI)</intervention_name>
    <description>MRI examinations performed on two devices: Ingernia 3 Testla (Philips) on the Horta site of the CHU Brugmann hospital, and Area 1,5 Tesla (Siemens) on the Brien site of the CHU Brugmann hospital. Diffusion sequences last 6 minutes and are already performed in the standard of care. Compared to the standard of care, one additional MRI will be performed one month after the start of the neo-adjuvant treatment, with diffusion analysis.The post-processing of the examinations will be realized with the Syngo Onco Care application of Siemens.</description>
    <arm_group_label>Breast cancer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Breast cancer

          -  Neo-adjuvant therapy indication

          -  Performance status from 0 to 2

        Exclusion Criteria:

          -  Contraindications to magnetic resonance imaging (pacemaker, nerve stimulator, cochlear
             implant, major claustrophobia)

          -  Absence of histological results

          -  Disruption of the neo-adjuvant therapy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mieke Cannie, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Brugmann</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nathalie Hottat, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Brugmann</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nathalie Hottat, MD</last_name>
    <phone>02 475 41 87</phone>
    <email>Nathalie.HOTTAT@chu-brugmann.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Brugmann</name>
      <address>
        <city>Brussels</city>
        <zip>1020</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathalie Hottat, MD</last_name>
      <phone>024754187</phone>
      <email>Nathalie.HOTTAT@chu-brugmann.be</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <reference>
    <citation>Fiorentino C, Berruti A, Bottini A, Bodini M, Brizzi MP, Brunelli A, Marini U, Allevi G, Aguggini S, Tira A, Alquati P, Olivetti L, Dogliotti L. Accuracy of mammography and echography versus clinical palpation in the assessment of response to primary chemotherapy in breast cancer patients with operable disease. Breast Cancer Res Treat. 2001 Sep;69(2):143-51.</citation>
    <PMID>11759820</PMID>
  </reference>
  <reference>
    <citation>Vinnicombe SJ, MacVicar AD, Guy RL, Sloane JP, Powles TJ, Knee G, Husband JE. Primary breast cancer: mammographic changes after neoadjuvant chemotherapy, with pathologic correlation. Radiology. 1996 Feb;198(2):333-40.</citation>
    <PMID>8596827</PMID>
  </reference>
  <reference>
    <citation>Huber S, Wagner M, Zuna I, Medl M, Czembirek H, Delorme S. Locally advanced breast carcinoma: evaluation of mammography in the prediction of residual disease after induction chemotherapy. Anticancer Res. 2000 Jan-Feb;20(1B):553-8.</citation>
    <PMID>10769724</PMID>
  </reference>
  <reference>
    <citation>Balu-Maestro C, Chapellier C, Bleuse A, Chanalet I, Chauvel C, Largillier R. Imaging in evaluation of response to neoadjuvant breast cancer treatment benefits of MRI. Breast Cancer Res Treat. 2002 Mar;72(2):145-52.</citation>
    <PMID>12038705</PMID>
  </reference>
  <reference>
    <citation>Sardanelli F, Boetes C, Borisch B, Decker T, Federico M, Gilbert FJ, Helbich T, Heywang-Köbrunner SH, Kaiser WA, Kerin MJ, Mansel RE, Marotti L, Martincich L, Mauriac L, Meijers-Heijboer H, Orecchia R, Panizza P, Ponti A, Purushotham AD, Regitnig P, Del Turco MR, Thibault F, Wilson R. Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group. Eur J Cancer. 2010 May;46(8):1296-316. doi: 10.1016/j.ejca.2010.02.015. Epub 2010 Mar 19.</citation>
    <PMID>20304629</PMID>
  </reference>
  <reference>
    <citation>Wu LM, Hu JN, Gu HY, Hua J, Chen J, Xu JR. Can diffusion-weighted MR imaging and contrast-enhanced MR imaging precisely evaluate and predict pathological response to neoadjuvant chemotherapy in patients with breast cancer? Breast Cancer Res Treat. 2012 Aug;135(1):17-28. doi: 10.1007/s10549-012-2033-5. Epub 2012 Apr 4. Review.</citation>
    <PMID>22476850</PMID>
  </reference>
  <reference>
    <citation>Li XR, Cheng LQ, Liu M, Zhang YJ, Wang JD, Zhang AL, Song X, Li J, Zheng YQ, Liu L. DW-MRI ADC values can predict treatment response in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy. Med Oncol. 2012 Jun;29(2):425-31. doi: 10.1007/s12032-011-9842-y. Epub 2011 Feb 1.</citation>
    <PMID>21286861</PMID>
  </reference>
  <reference>
    <citation>Just N. Improving tumour heterogeneity MRI assessment with histograms. Br J Cancer. 2014 Dec 9;111(12):2205-13. doi: 10.1038/bjc.2014.512. Epub 2014 Sep 30. Review.</citation>
    <PMID>25268373</PMID>
  </reference>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 9, 2016</study_first_submitted>
  <study_first_submitted_qc>June 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2016</study_first_posted>
  <last_update_submitted>July 25, 2016</last_update_submitted>
  <last_update_submitted_qc>July 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brugmann University Hospital</investigator_affiliation>
    <investigator_full_name>Mieke Cannie</investigator_full_name>
    <investigator_title>Head of service</investigator_title>
  </responsible_party>
  <keyword>Diffusion Weighted Magnetic Resonance Imaging</keyword>
  <keyword>Breast cancer</keyword>
  <keyword>Neo-adjuvant therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Body Weight</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

